二极管激光联合术中丝裂霉素C在内眦部激光泪囊鼻腔造孔术中的应用
Use of the diode laser with intraoperative mitomycin C in endocanalicular laser dacryocystorhinostomy.
作者信息
Henson Raoul D, Henson Ruben G, Cruz Hernando L, Camara Jorge G
机构信息
St. Luke's International Eye Institute, St. Luke's Medical Center, Quezon City, Philippines.
出版信息
Ophthalmic Plast Reconstr Surg. 2007 Mar-Apr;23(2):134-7. doi: 10.1097/IOP.0b013e31802f208d.
PURPOSE
To determine the safety and efficacy of the diode laser with intraoperative mitomycin C in endocanalicular laser dacryocystorhinostomy (ECL-DCR).
METHODS
In a prospective case series of 40 ECL-DCRs using the diode laser, mitomycin C was placed intraoperatively in all cases. The main outcome measure was resolution or improvement of epiphora and no major laser damage intranasally. Patients were followed for at least 18 months.
RESULTS
Forty consecutive ECL-DCRs on 30 patients (23 females, 7 males, mean age 62 years) were performed from April 2000 to December 2001. The success rate at 12 months postoperatively was 87.5%. All failures were due to a constricted nasal osteotomy. No significant intraoperative or postoperative complications were recorded.
CONCLUSIONS
Diode laser ECL-DCR with mitomycin C appears to be a safe and effective treatment modality for primary acquired nasolacrimal duct obstruction.
目的
确定在泪道内激光泪囊鼻腔造口术（ECL-DCR）中使用二极管激光联合术中丝裂霉素C的安全性和有效性。
方法
在一项使用二极管激光进行40例ECL-DCR的前瞻性病例系列研究中，所有病例术中均使用丝裂霉素C。主要观察指标为溢泪症状的缓解或改善以及鼻内无严重激光损伤。对患者进行至少18个月的随访。
结果
2000年4月至2001年12月，对30例患者（23例女性，7例男性，平均年龄62岁）连续进行了40例ECL-DCR。术后12个月的成功率为87.5%。所有失败均归因于鼻骨切开术狭窄。未记录到明显的术中或术后并发症。
结论
二极管激光ECL-DCR联合丝裂霉素C似乎是治疗原发性后天性鼻泪管阻塞的一种安全有效的治疗方式。
Zotero 插件